Oncocyte (NASDAQ:IMDX) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Oncocyte (NASDAQ:IMDX – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently issued reports on IMDX. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price objective on shares of Oncocyte in a research note on Tuesday, August 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a research report on Monday, September 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oncocyte presently has an average rating of “Hold” and a consensus price target of $10.50.

Get Our Latest Research Report on Oncocyte

Oncocyte Stock Performance

NASDAQ:IMDX opened at $3.44 on Friday. The stock has a fifty day moving average price of $4.20 and a 200-day moving average price of $4.61. The company has a market cap of $112.56 million, a price-to-earnings ratio of -2.31 and a beta of 1.80. Oncocyte has a fifty-two week low of $2.42 and a fifty-two week high of $8.51.

Oncocyte (NASDAQ:IMDX – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million during the quarter.

About Oncocyte

(Get Free Report)

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy.

The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy.

Further Reading